How to bridge the production gap in gene therapy

Transkript Spezial Bio Boston – May, 2018

Significant scientific breakthroughs in molecular biology over the last decade also fueled gene therapy development. As the number of clinical trials in gene therapy applications increases, the need for industrial scale viral vector production follows. Current production systems cannot keep up with the growing demand — the market is urgently looking for novel solutions.

CEVEC Pharmaceuticals GmbH, a German-based expert in the production of tailor-made recombinant glycoproteins and gene therapy vectors, has developed what scientists are looking for — fully scalable, clinical-grade good manufacturing practice (GMP) compatible solutions for gene therapies.